Boicean Adrian, Ichim Cristian, Todor Samuel Bogdan, Anderco Paula, Popa Mirela Livia
Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania.
Diagnostics (Basel). 2024 Apr 23;14(9):861. doi: 10.3390/diagnostics14090861.
The role of the intestinal microbiota in the diagnosis and treatment of pancreatic diseases is increasingly significant. Consequently, fecal microbiota transplantation (FMT) is emerging as a promising therapeutic avenue for various pancreatic disorders, including cancer, pancreatitis, and type 1 diabetes (T1D). This innovative procedure entails transferring gut microbiota from healthy donors to individuals affected by pancreatic ailments with the potential to restore intestinal balance and alleviate associated symptoms. FMT represents a pioneering approach to improve patient outcomes in pancreatic diseases, offering tailored treatments customized to individual microbiomes and specific conditions. Recent research highlights the therapeutic benefits of targeting the gut microbiota for personalized interventions in pancreatic disorders. However, a comprehensive understanding of the intricate interplay between gut microbiota and pancreatic physiology warrants further investigation. The necessity for additional studies and research endeavors remains crucial, especially in elucidating both adult and pediatric cases affected by pathological pancreatic conditions.
肠道微生物群在胰腺疾病的诊断和治疗中的作用日益显著。因此,粪便微生物群移植(FMT)正成为治疗各种胰腺疾病(包括癌症、胰腺炎和1型糖尿病(T1D))的一种有前景的治疗途径。这种创新方法需要将健康供体的肠道微生物群转移到受胰腺疾病影响的个体身上,有可能恢复肠道平衡并缓解相关症状。FMT是一种改善胰腺疾病患者预后的开创性方法,提供针对个体微生物群和特定病症的定制治疗。最近的研究强调了针对肠道微生物群进行胰腺疾病个性化干预的治疗益处。然而,要全面了解肠道微生物群与胰腺生理之间复杂的相互作用,仍需要进一步研究。进行更多研究和探索的必要性仍然至关重要,特别是在阐明受胰腺病理状况影响的成人和儿童病例方面。